Fig. 2From: Insight into the hepatoprotective, hypolipidemic, and antidiabetic impacts of aliskiren in streptozotocin-induced diabetic liver disease in miceEffect of one month treatment with aliskiren on Cholesterol level in STZ-induced diabetes in mice. Each value represents mean of 8 mice. Statistical analysis was carried out using one way analysis of variance (ANOVA) followed by Tukey Kramer multiple comparisons test. *Significantly different from Normal control at P < 0.05. #Significantly different from Diabetic control at P < 0.05Back to article page